{
    "clinical_study": {
        "@rank": "126087", 
        "acronym": "SOS", 
        "arm_group": [
            {
                "arm_group_label": "Switch ritonavir-boosted PI", 
                "arm_group_type": "Experimental", 
                "description": "Switch their existing ritonavir-boosted PI to another potent ART drug with lesser effects on serum cholesterol selected by the investigator."
            }, 
            {
                "arm_group_label": "Continue ritonavir-boosted PI+Rosuvastatin", 
                "arm_group_type": "Experimental", 
                "description": "Continue ritonavir-boosted PI-based ART and commence rosuvastatin 10 mg daily (5 mg daily in Asian participants)."
            }
        ], 
        "brief_summary": {
            "textblock": "To compare the effect of rosuvastatin to protease inhibitor switching on fasting total\n      cholesterol over 12 weeks."
        }, 
        "brief_title": "Treatment With Rosuvastatin Versus Switching PI (Protease Inhibitor) in Patients HIV With High Cholesterol Levels", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "HIV", 
            "Hypercholesterolaemia"
        ], 
        "condition_browse": {
            "mesh_term": "Hypercholesterolemia"
        }, 
        "detailed_description": {
            "textblock": "To compare the effects of rosuvastatin to protease inhibitor switching on:\n\n        -  Total cholesterol through week 12\n\n        -  Safety parameters (HIV viral load, clinical adverse events, serious adverse events,\n           laboratory adverse events, modifications to antiretroviral therapy)\n\n        -  Quality of life (SF-12)\n\n        -  Fasting LDL cholesterol (estimated with Friedewald equation unless triglycerides\n           >400mg/dL, in which case LDL-C would be measured directly), HDL cholesterol, total :\n           HDL cholesterol ratio, LDL particles sizes, triglycerides\n\n        -  Fasting glucose and insulin\n\n        -  Framingham cardiovascular risk score\n\n        -  D:A:D 5-year estimated risk calculator"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  HIV-positive status\n\n          -  Adults (\u226518 years of age)\n\n          -  Stable and well-tolerated combination ART including a ritonavir-boosted protease\n             inhibitor for the previous 6 months\n\n          -  HIV RNA <50 copies/mL for at least the preceding 3 months\n\n          -  Fasting total cholesterol \u22655.5 mmol/L (>213 mg/dL)\n\n          -  Framingham risk score \u22658% at 10 years OR diabetes mellitus OR a family history of\n             premature coronary artery disease in a first-degree relative\n\n          -  Provision of written, informed consent\n\n        Exclusion criteria:\n\n          -  Any statin in the previous 12 weeks\n\n          -  Previous statin-induced myopathy or hepatitis\n\n          -  History of coronary artery disease, stroke or any other indication for the use of\n             statin therapy (hyperlipidaemia: genetic, secondary or idiopathic)\n\n          -  Concurrent use of:\n\n               1. oral corticosteroids use other than for replacement therapy (i.e. prednisolone\n                  5-7.5 mg, hydrocortisone 20-30 mg, cortisone acetate 25-37.5 mg daily)\n\n               2. other immunosuppressive or immunomodulating drugs\n\n          -  Contraindication to rosuvastatin therapy:\n\n               1. liver transaminases >5 times the upper normal limit\n\n               2. creatinine clearance <30 mL/min\n\n               3. known myopathy\n\n               4. current fibrate therapy\n\n               5. known resistance to one or more \"backbone\" ART drugs\n\n          -  No potent switch ART drug available to replace the current ritonavir-boosted protease\n             inhibitor\n\n          -  Known intolerance to rosuvastatin or the proposed switch ART drug\n\n          -  Women attempting or likely to become pregnant, or who are pregnant or breast-feeding\n\n          -  A patient with a history or current evidence of any condition, therapy, or laboratory\n             abnormality, or other circumstance that might confound the results of the study, or\n             interfere with the patient's participation for the full duration of the study\n\n          -  Unable to complete study procedures"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01935674", 
            "org_study_id": "SOS"
        }, 
        "intervention": [
            {
                "arm_group_label": "Switch ritonavir-boosted PI", 
                "description": "Switch their existing ritonavir-boosted PI to another potent ART drug with lesser effects on serum cholesterol selected by the investigator.", 
                "intervention_name": "Switch ritonavir-boosted PI", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Continue ritonavir-boosted PI+Rosuvastatin", 
                "description": "Continue ritonavir-boosted PI-based ART and commence rosuvastatin 10 mg daily (5 mg daily in Asian participants).", 
                "intervention_name": "Continue Ritonavir-boosted PI+Rosuvastatin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Protease Inhibitors", 
                "Ritonavir", 
                "HIV Protease Inhibitors", 
                "Rosuvastatin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Hypercholesterolaemia", 
            "HIV", 
            "Rosuvastatin", 
            "Protease inhibitor switching"
        ], 
        "lastchanged_date": "September 2, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Barcelona", 
                    "country": "Spain", 
                    "zip": "08036"
                }, 
                "name": "Hospital Clinic of Barcelona"
            }
        }, 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "2", 
        "official_title": "Rosuvastatin Versus Protease Inhibitor Switching for Hypercholesterolaemia in HIV-infected Adults", 
        "overall_contact": {
            "email": "jpich@clinic.ub.es", 
            "last_name": "Judit Pich", 
            "phone": "0034932275400", 
            "phone_ext": "2815"
        }, 
        "overall_contact_backup": {
            "email": "estebanm@clinic.ub.es", 
            "last_name": "Esteban Martinez, MD"
        }, 
        "overall_official": {
            "affiliation": "Hospital Cl\u00ednic i Provincial de Barcelona", 
            "last_name": "Esteban Martinez, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Percentage change from baseline in total cholesterol at 12 weeks.", 
            "safety_issue": "No", 
            "time_frame": "Baseline and 12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01935674"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Hospital Clinic of Barcelona", 
            "investigator_full_name": "Juan A. Arnaiz", 
            "investigator_title": "Project manager", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Total cholesterol through week 12", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Safety parameters (HIV viral load, clinical adverse events, serious adverse events, laboratory adverse events, modifications to antiretroviral therapy)", 
                "safety_issue": "Yes", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Quality of life (SF-12)", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Fasting LDL cholesterol (estimated with Friedewald equation unless triglycerides >400mg/dL, in which case LDL-C would be measured directly), HDL cholesterol, total : HDL cholesterol ratio, LDL particles sizes, triglycerides", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Fasting glucose and insulin.", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Framingham cardiovascular risk score.", 
                "safety_issue": "No", 
                "time_frame": "Screening and week 12."
            }, 
            {
                "measure": "D:A:D 5-year estimated risk calculator.", 
                "safety_issue": "No", 
                "time_frame": "Screening and week 12."
            }
        ], 
        "source": "Hospital Clinic of Barcelona", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Juan A. Arnaiz", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}